Reduction of SCD163, SP and PD1+ Th cell levels in a phase 1B trial of the NK1R antagonist aprepitant

Authors
Category Primary study
JournalTopics in Antiviral Medicine
Year 2014
This article has no abstract
Epistemonikos ID: ff553604700fc730f8e8bd3ec1030c6995b3f644
First added on: Feb 07, 2025